MassMutual Private Wealth & Trust’s Theravance Biopharma TBPH Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.56K	Sell	327 -68	-17%	-$1.13K	﹤0.01%	1636
2026 Q1	$6.41K	Buy	395 +294	+291%	+$5.2K	﹤0.01%	1567
2025 Q4	$1.89K	Buy	101 +68	+206%	+$1.13K	﹤0.01%	2007
2025 Q3	$482	Hold	33	–	–	﹤0.01%	2242
2025 Q2	$364	Buy	+33	New	+$321	﹤0.01%	2260
2024 Q1	–	Sell	-42	Closed	-$472	–	2129
2023 Q4	$472	Sell	42 -142	-77%	-$1.43K	﹤0.01%	1830
2023 Q3	$1.59K	Hold	184	–	–	﹤0.01%	1565
2023 Q2	$1.9K	Hold	184	–	–	﹤0.01%	1482
2023 Q1	$2K	Hold	184	–	–	﹤0.01%	1425
2022 Q4	$2K	Hold	184	–	–	﹤0.01%	1338
2022 Q3	$2K	Buy	+184	New	+$1.72K	﹤0.01%	1292
2021 Q4	–	Sell	-39	Closed	–	–	1485
2021 Q3	$0	Buy	+39	New	+$436	﹤0.01%	1335
2015 Q3	–	Sell	-11	Closed	-$140	–	865
2015 Q2	$351	Buy	+11	New	+$171	﹤0.01%	707

Other funds holding TBPH

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

SSA

Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

JWS

Juncture Wealth Strategies Scottsdale, Arizona $384M AUM 27.62% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

JIR

James Investment Research Alpha, Ohio $984M AUM 36.03% 1-Year Est. Return

Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

MassMutual Private Wealth & Trust's TBPH Position: Q2 2026 in Review

MassMutual Private Wealth & Trust reduced its Theravance Biopharma (TBPH) stake by 17% in Q2 2026, selling an estimated $1.13K and leaving 327 shares worth $5.56K. The position accounts for ﹤0.01% of the portfolio, ranked #1636.

MassMutual Private Wealth & Trust first reported a position in TBPH in Q2 2015 and has held it in 13 quarters since. The position peaked at $6.41K in Q1 2026. 31 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

MassMutual Private Wealth & Trust held 327 shares of Theravance Biopharma worth $5.56K as of Q2 2026.
MassMutual Private Wealth & Trust sold 68 Theravance Biopharma shares in Q2 2026, an estimated $1.13K.
Theravance Biopharma made up ﹤0.01% of MassMutual Private Wealth & Trust's portfolio in Q2 2026, its #1636 holding.
MassMutual Private Wealth & Trust first reported a position in Theravance Biopharma in Q2 2015 and has held it in 13 quarters since.
MassMutual Private Wealth & Trust's Theravance Biopharma position peaked at $6.41K in Q1 2026.
31 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.